Domagrozumab

Domagrozumab (PF-06252616) (INN) is a humanized monoclonal antibody designed for the treatment of Duchenne muscular dystrophy.[1][2]

Domagrozumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetGDF-8
Clinical data
Other namesPF-06252616
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6366H9826N1690O2008S46
Molar mass143639.22 g·mol−1

This drug was developed by Pfizer.

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.